Research paper

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells

Alessio Ugolini, Ilaria Grazia Zizzaria, Fulvia Ceccarellib, Andrea Botticellib, Tania Colasanti, Lidia Strigarid, Aurelia Rughetti, Hassan Rahimia, Fabrizio Contib, Guido Valesinib, Paolo Marchettic, Marianna Nutia*

a Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
b Arthritis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
c Oncology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
d Medical Physics Unit, S. Orsola-Malpighi Hospital, Bologna, Italy

ARTICLE INFO

Article History:
Received 19 June 2020
Revised 7 September 2020
Accepted 14 October 2020
Available online xxx

ABSTRACT

Background: ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions. Autoantibodies can be related with a dysfunctional immune system, although their association with immune-based anti-cancer therapies has never been investigated. Moreover, so far no reliable predictive factor is currently available to aid in treatment selection. CD137+T-cells are largely known to be the anti-tumor activated effector cells, but they have never been associated with the response to immunotherapies.

Methods: Forty-two patients with metastatic NSCLC receiving anti-PD-1 ICIs at Sant’Andrea Hospital and Poli-clinico Umberto I, from June 2016 to September 2018 were enrolled. Circulating levels of IgM-Rheumatoid Factor were evaluated at baseline and correlated with patients clinical response following the anti-PD-1 treatment. IgM-RF interaction and effect on T-cells in vivo and in vitro were investigated.

Findings: IgM-RF in NSCLC patient sera strongly predicted the development of early progression to ICIs. Also, a significant reduction of progression-free survival rate in anti-PD-1 treated patients could be identified when patients were stratified based on IgM-RF positivity and titers. IgM-RF bound preferentially circulating naïve and central memory T-cells and a significant reduction of CD137+ anti-tumor T effector cells was found in IgM-RF positive patients. In addition, a higher percentage of CD137+T-cells in peripheral blood of NSCLC patients at baseline resulted as a strong independent prognostic factor for a better outcome in terms of PFS and OS after the anti-PD-1 treatment. Furthermore, T-cells exposed to IgM-RF showed a robust defect in their migratory ability in response to CCL19 chemokine.

Interpretation: In this study we showed that serum IgM-RF can be regarded as predictive factor for the development of early progression and prognostic factor of a reduced progression-free survival and overall-survival in anti-PD-1 treated NSCLC patients. The ability of IgM-RF to bind naïve and central memory T-cells and impair their migration could make account for the reduction of the tumor-reactive CD137+ T-cells population that may cause a non-effectiveness of these T-cells targeting drugs.

Funding: AIRC, MIUR and Sapienza University of Rome.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Despite recent progresses in cancer treatment obtained with novel immunotherapies, several patients show a primary or secondary resistance, leading to fast progressions. The mechanisms of this resistance remain unknown, but different hypothesis can be outlined. Doubtless, host related factors and the fitness of patient immune system may contribute [1]. Indeed, the identification of immune biomarkers that can aid clinicians in the choice of the right therapy to reach the maximum benefit for the patient is of utmost importance.

The relation between autoimmune diseases and cancer is currently an emerging area of interest since it still remains a clinically challenging issue. In fact, some of the pathogenic mechanisms are shared between these two conditions, although direct proof of their role as causative factors is lacking, as in the case of serum autoantibodies [2].
**Research in context**

*Evidence before this study*

We searched PubMed on Sept 4, 2018, using the following terms: “Immune Checkpoint Inhibitors AND NSCLC AND resistance OR early progression OR autoimmunity OR autoantibodies” AND “Rheumatoid Factor AND cancer” AND “Rheumatoid Factor AND isotopes OR role OR healthy subjects”. The search was not limited by date, but was limited to articles and abstracts published in English only. From these studies we could point out that several NSCLC patients undergoing an ICI treatment developed fast resistance to the therapy leading to fast progressions; however it was not possible to identify a biomarker capable of predicting the response to the immunotherapy. A thorough review of the literature also showed as RF in patient sera could be associated with an higher risk of developing cancer, but the biological mechanism was unknown. Moreover, even if the relation between autoimmune diseases and cancer was already established, researches about the possible association between the presence of autoantibodies in sera and the response to the immunotherapies were lacking.

*Added value of this study*

Results of this retrospective study show that IgM-RF in patient sera is both a predictive factor for the development of early progression in response to an anti-PD-1 treatment and also an important prognostic factor for a progressive disease, probably due to its ability of impairing central memory and naïve T-cell migration and a subsequent reduction of CD137+ anti-tumor T effector cells in RF-positive patients. The percentage of CD137+ T-cells at baseline strongly influenced NSCLC patients’ outcome in response to the anti-PD-1 treatment. This study represents, to the best of our knowledge, the first evidence of IgM-RF as a possible biomarker that can predict the T-cell fitness of NSCLC patients and thus their capability to respond to an anti-PD-1 treatment. We also demonstrated for the first time that the CD137+ T-cell population is a key factor in driving the NSCLC patients response to the immunotherapies. Moreover, this study identifies IgM-RF as a novel prognostic factor for a progressive disease and a worse outcome in NSCLC patients.

*Implications of all the available evidence*

Our data suggest that the dosage of IgM-RF in NSCLC patients can be introduced in the routine clinical practice in order to select the correct therapeutic plan to get the best patient response. Moreover, our study indicates that the presence of IgM-RF and the percentage of CD137+ T-cells at baseline can be considered together with the other well established prognostic factors in order to improve NSCLC patients stratification. Further studies including higher numbers of patients and different types of tumors will be needed to extend the knowledge about this new biomarker.

Rheumatoid Factors (RFs) are autoantibodies which bind the constant regions (Fc) of IgGs and mainly occur as IgM antibodies (IgM-RF). RF was initially discovered in serum of patients with Rheumatoid Arthritis (RA) of which IgM-RF is still considered a fundamental marker for the diagnosis and prognosis [3,4]. Later, it was highlighted that RFs could also be found in high titers in sera of patients with other diseases (both autoimmune and non-autoimmune) in the same way as healthy subjects [5,6]. About the possible role of RFs in cancer, little is known. Some studies suggested the possible correlation between RFs concentrations in patient sera and the increase of cancer risk [7–10], tumor recurrence and load [11,12], but no biological mechanism has been described. Moreover, the clinical association between RFs and the response to immunotherapies has never been investigated. This can be a crucial issue in ICI treatments, since RFs are autoantibodies directed against IgGs (the belonging class of ICIs monoclonal antibodies) and, differently from other autoantibodies, can be found in high titers in healthy subjects.

The CD137+ T-cell population has been largely referred as the real T effector cells population activated against cancer cells [13,14], but its role as a possible driver of the response to the immunotherapies in oncologic patients has never been probed.

In this study, we retrospectively assayed the IgM-RF levels in the sera of non-small cell lung cancer (NSCLC) patients in treatment with two anti-PD-1 immune-checkpoint inhibitors (ICIs), Nivolumab and Pembrolizumab, in order to identify a possible association between the failure of T-cells based therapies and an altered immune system.

**2. Methods**

**2.1. Patients**

Patients with metastatic NSCLC receiving Nivolumab or Pembrolizumab at “Sant’Andrea” Hospital and “Pollicino Umberto I”, “Sapienza” University of Rome from June 2016 to September 2018 were enrolled in this study. Inclusion criteria were: age > 18 years; histologically-documented diagnosis of NSCLC; metastatic disease; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; measurable disease; adequate cardiac, pulmonary, renal, liver and bone marrow function; patients with stable and asymptomatic central nervous system metastases were eligible. Exclusion criteria were: autoimmune diseases; symptomatic interstitial lung disease and any other significant comorbidity; systemic immunosuppression; prior treatment with immune-stimulatory antitumor agents including checkpoint-targeted agents. Blood samples and sera has been collected from the patients before the beginning of anti-PD-1 treatment (T0) and at different time-points during the treatment for IgM-RF dosage. IgM-RF and anti-cyclic citrullinated peptide (anti-CCP) autoantibodies were detected by using commercial ELISA kits (Diamexid, 720,710 for IgM-RF and DELTA BIOLOGICALS, CD-117 for anti-CCP): the results were evaluated according to the manufacturers’ instructions. Peripheral Blood Mononuclear Cells (PBMCs) have been collected and frozen for 32 patients at T0 and then thawed for flow cytometry analysis.

**2.2. Treatment, efficacy and safety assessments**

Nivolumab was administered intravenously at a standard dose of 3 mg/kg every 2 weeks and Pembrolizumab was administered intravenously at a standard dose of 200 mg every 3 weeks until disease progression or development of unacceptable toxicity. Tumor response was assessed according to clinical practice thereafter until disease progression using immune-related Response Evaluation Criteria in Solid Tumors Criteria (i-RECIST) and classified according to disease control (complete response, partial response and stable disease) and progressive disease (PD). Safety assessments were performed at day 1 of every cycle until the end of treatment and toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).

**2.3. Objectives and outcomes**

Progression-free survival (PFS) was defined as the time from ICIs commencement until the first documented tumor progression or death from any cause, whichever occurred first. Early progressor patients were defined as those experiencing disease progression...
within 3 months from the beginning of ICIs treatment. Overall survival (OS) was defined as the time from Nivolumab or Pembrolizumab commencement to death from any cause. Data for patients who were alive and did not have disease progression or who were lost to follow-up were censored for the analysis of progression-free survival and overall survival at the time of the last imaging assessment.

2.4. In vitro T-cells assays

Human T-lymphocytes were purified from PBMCs of healthy donors (Ethical Committee Protocol, RIF.CE: 4212) after Hypaque/Ficoll (Cedaredane, CLS020) gradient by EasySepTM Human CD3 Positive Selection Kit II (StemCell Technologies, 17,851) and cultured (100.000 cells/100µl) in RPMI 1640 (HyClone, R8758) supplemented with 2 mM L-glutamine (Sigma-Aldrich, G8540), penicillin 100 U/ml, streptomycin 100 µg/ml (Penicillin-Streptomycin solution, Sigma-Aldrich, P4333) with 5% heat-inactivated Fetal Bovine Serum (FBS) (HyClone, SH30071.01). T-cell purity (>90%) was checked prior to each experiment by flow cytometer (FC).

IgM-RFs prepared from human plasma (Athens Research and Technology, 16–16–180.603) and control IgM prepared from plasma of multiple myeloma (MM) patients (Athens Research and Technology, 16–16–090.713-M) (the antibodies have been dialyzed prior to the usage to remove sodium azide) were added to T-cells cultures for 24 h at the concentration of 50 µg/ml (based on IgM-RF titers in positive patient sera), Nivolumab (Bristol–Myers Squibb, BMS) was added for 24 h at the concentration of 25 µg/ml.

For the proliferation assay, PBMCs were stimulated with PHA (5 µg/ml) (Sigma-Aldrich, 61,764) for 4 days at 37 °C in the presence or absence of IgM-RF and the control IgM; PBMCs were pre-treated with CarboxyFluorescin Succinimidyl Ester (1 µM, CFSE) (Life Technologies, C34554) and cell proliferation was monitored through progressive halving of fluorescence in CD3+ labelled cells using FACS analysis software (Becton Dickinson, BD).

For the migration assay purified CD3+ T-cells were activated with PHA (5 µg/ml) for 3 days at 37 °C and cultured for other 24 h with IgM-RF, control IgM or left untreated; cells were then collected, washed twice, re-suspended in migration media (RPMI, 0.1% FBS, 10 mM HEPES) and then were allowed to migrate for 2 h through a 5 µm pore size Transwell inserts (Corning, CLS3421–48). Cells from the bottom chamber were thus harvested and counted for 1 min using FACS flow cytometer running FACS Diva data acquisition and analysis software (Becton Dickinson, BD).

Cell viability was checked by 7-AAD (BD, 559,925) prior to each experiment.

2.5. T-cell phenotype

T-cell phenotype was performed by FC employing the following monoclonal antibodies (MoAbs): anti-CD3-BV510 (BioLegend, 317,332), anti-CD4-ApcH7 (BD, 560,158), anti-CD8-Percp5.5 (BioLegend, 344,710), anti-CCR7-FITC (BioLegend, 353,216), anti-CD45RA-Apc (BioLegend, 304,112), anti-PD-1-PE (BioLegend, 621,608), anti-IgM-BV421 (BioLegend, 314,516), anti-CD137-Pecy7 (BioLegend, 309,818) and 7-AAD (BD, 559,925). Cells were incubated with Fc-block (BioLegend, 101,302) for 5 min and surface staining was performed at 4 °C for 15 min. At least 10^6 events were evaluated using a FACScantoll flow cytometer.

2.6. Statistical analysis

To compare early progressions, Odd ratios with associated 95% confidence intervals and p values were calculated with the use of a Woolf logit model and Pearson's Chi-square test; when a group resulted in zero event, it was computed as 0.5 for the OR estimate and its 95% CI. We performed pre-specified clinical subgroups analyses to assess the power of IgM-RF as predictive factor, using ORs that were estimated from a Woolf logit model.

We evaluated the possible association between IgM-RF positivity and the other clinical characteristics using ORs with associated 95% confidence intervals and p-values that were estimated from a Woolf logit model.

The impact of clinic-pathological variables on progression-free survival (PFS) was analyzed by both the univariate and multivariate analyses (UVA and MVA, respectively). With regards to UVA, patients' PFS was analyzed using the Kaplan–Meier method and log-rank tests to obtain Hazard Ratios with associated 95% confidence intervals and p values. Prognostic clinic-pathological variables deemed of potential relevance in the univariate analysis (corresponding to a cutoff of \( p < 0.10 \)) were included in the multivariate Cox proportional hazards regression analysis. The forward stepwise analysis was conducted with a P-IN = 0.05 and a P-OUT = 0.10.

Patients' Overall Survival (OS) was analyzed using the Kaplan–Meier method and log-rank tests to obtain Hazard Ratios with associated 95% confidence intervals and p values.

For the other experiments, Student's t-test and one-way Anova test were used. A \( p < 0.05 \) was considered statistically significant. When more than two groups have been compared, p values were corrected for multiple comparisons.

The calculated p-value have been corrected for multiple tests using the Bonferroni correction, so the calculated p-value needs to be multiplied for the number of tests and compared with the cutoff p-value of 0.03.

2.7. Ethics

The study was conducted in accordance with good clinical practice guidelines and the declaration of Helsinki. The final version of the protocol was approved by the Institutional Ethics Committee of the two “Sapienza” Hospital Centers involved (Ethical Committee approval, protocol n° 805/16, RIF.CE: 4181).

All the patients gave written informed consent.

2.8. Role of the funding source

The study was funded by AIRC (MN: AIRC/2015), MIUR (MN: C26H15Y42B) and “Sapienza” University of Rome (MN: Sapienza University 2016). The funding sources had no role in the study design, in the collection, analysis and interpretation of data.

3. Results

3.1. Patients characteristics

From June 2016 to September 2018 a total of 42 metastatic NSCLC patients who were about to begin an anti-PD-1 therapy with Nivolumab or Pembrolizumab as first, second, third or fourth line treatment were enrolled. Five patients were administered with Pembrolizumab, while 37 were administered with Nivolumab. Response to the immunotherapy has been monitored, evaluating in particular early progressions (within 3 months). Table 1 reports patient clinical characteristics.

Among these patients, 57.1% had Squamous-cell carcinoma, while 38.1% had Adenocarcinoma. The average age was 67.8 years, 92.9% of
them were former or current smokers, 23.8% had a previous surgery, while 9.6% had an adjuvant chemotherapy ± radiotherapy.

At the UVA, the ECOG PS and the sites of metastasis at the beginning of ICIs treatment resulted significant prognostic factors for a Progressive Disease (PD), as already shown [15] (Fig. S1).

### 3.2. IgM-RF predicts early progression and is a prognostic factor for a progressive disease in NSCLC patients

IgM-RF titers were evaluated in the enrolled NSCLC patients at T0: 11 out of 42 (26.2%) were positive for IgM-RF (RFpos, values > 50 IU/ml). Our patients were also tested for anti-CCP autoantibodies: none of them resulted positive. None of the RFpos patients could be classified as affected by RA or other autoimmune diseases. We further stratified RFpos patients in highly positive (RFhigh subgroup, values > 50 IU/ml) and slightly positive (RFlow subgroup, values ≥16 and < 50 IU/ml) (Table 2).

When looking at the possible associations between IgM-RF positivity and the other patients clinical characteristic (Table S1), not surprisingly it resulted significantly associated (OR, 4.83; 95% CI, 0.89 to 25.92; p = 0.05; Woolf logit model and Pearson’s Chi-square test) only with an older age (> 68 years) of the patients, as previously reported [16–19].

IgM-RF levels did not change through different time-points of ICIs treatment (both Nivolumab and Pembrolizumab) for each patient (Fig. S2), thus suggesting that the production and the levels of the autoantibody were not influenced neither by the ICIs treatment itself nor by the progression and tumor load. Surprisingly, the presence of IgM-RF in patient sera strongly correlated with the development of a fast resistance to the anti-PD-1 treatment and thus with early progression; in addition, all the patients with high IgM-RF levels were early progressors (Table 2 and Fig. 1a). Indeed, early progression was observed in 73% of RFpos patients, while it occurred in only 26% of RF-negative (RFneg) patients (p = 0.005, Chi-square test). The power of IgM-RF as a predictive factor for the risk of developing early progression was calculated with the estimate of the odd ratio, comparing RFpos vs RFneg patients. Considering that 1 represents the risk in RFneg patients, the power of IgM-RF positivity as predictive factor resulted high in both the overall population (OR, 7.66; 95% CI, 1.62 to 36.18; p = 0.005; Woolf logit model and Pearson’s Chi-square test) and in most of clinical subgroups (Fig. 1b). IgM-RF resulted not relevant in patient ≥ 68 years and with ECOG PS = 2, two subgroups in which clinical and immunological parameters are most probably already compromised. On the other side, it gained validity [OR, 51.67; 95% CI, 1.61 to 1657; p = 0.0008; Woolf logit model and Pearson’s Chi-square test] in the group characterized by a young age (< 68 years), thus strengthening its role as independent predictive factor even when its presence is not accompanied by other compromising factors.

In addition, at the UVA, the IgM-RF positivity was a significant prognostic factor for a PD; indeed, the PFS was significantly shorter (p = 0.035, Kaplan–Meier method and log-rank tests) with a median PFS of 75 days in RFpos patients compared to RFneg patients, for which the median PFS was 240 days (Fig. 2a, b). A significant increase of the probability to develop a PD following ICIs therapy and a lower PFS rate (p = 0.0024, Kaplan–Meier method and log-rank tests) was also associated to IgM-RF titers when patients were divided in RF subgroups (Fig. 2a, b). Moreover, at both the MVA methods we used, the RF positivity or RF values and the ECOG PS retained their statistical significance as prognostic factors; both MVA tested methods resulted equally valid and significant (p = 0.001, Cox proportional hazards regression analysis) (Fig. 2b). Sites of metastases has also been included as input variable in the multivariate analyses, being a significant factor in the univariate analysis. For the forward stepwise analysis, a P-IN = 0.05 and a P-OUT = 0.10 were used. Of note, the forward stepwise selection method did not retain this variable in the final models because they did not significantly improve the prediction of the two calculated models. Therefore, only the variables with statistically significant results were added in the table, reporting their HR and 95% CI.

### Table 1

Characteristics of the patients at enrollment, according to IgM-RF positivity.

| Characteristic | All patients N = 42 | Patients RFneg N = 31 | Patients RFpos N = 11 |
|----------------|---------------------|-----------------------|----------------------|
| Age - yr Mean ± SD | 67.8 ± 9.8 | 66.8 ± 10.7 | 70.9 ± 5.9 |
| Sex - no (%) male | 28 (66.6) | 19 (61.3) | 9 (81.8) |
| female | 14 (33.3) | 12 (38.7) | 2 (18.2) |
| Histologic diagnosis - no (%) | | | |
| Adenocarcinoma | 16 (38.1) | 10 (32.2) | 6 (54.5) |
| Squamous-cell carcinoma | 24 (57.1) | 20 (64.5) | 4 (36.4) |
| Other | 2 (4.8) | 1 (3.2) | 1 (9.1) |
| Smoking status - no (%) | | | |
| Never | 3 (7.1) | 2 (6.4) | 1 (9.1) |
| Former or current | 39 (92.9) | 29 (93.6) | 10 (90.9) |
| Previous surgery - no (%) | | | |
| Yes | 10 (23.8) | 7 (22.6) | 3 (27.3) |
| No | 32 (76.2) | 24 (77.4) | 8 (72.7) |
| Adjuvant chemotherapy ± radiotherapy - no (%) | | | |
| Yes | 4 (9.6) | 2 (6.4) | 2 (18.2) |
| No | 38 (90.4) | 29 (93.6) | 9 (81.8) |
| ECOG Performance status score - no (%) | | | |
| 0 | 17 (40.5) | 14 (45.2) | 3 (27.3) |
| 1 | 20 (47.6) | 14 (45.2) | 6 (54.5) |
| 2 | 5 (11.9) | 3 (9.6) | 2 (18.2) |
| Sites of metastasis at beginning of ICI treatment - no (%) | | | |
| 1 site | 7 (16.7) | 5 (16.1) | 2 (18.2) |
| 2 sites | 19 (45.3) | 12 (38.7) | 7 (63.6) |
| 3 sites | 8 (19) | 8 (26) | 0 (0) |
| > 3 sites | 8 (19) | 6 (19.2) | 2 (18.2) |
| ICIs line of treatment - no (%) | | | |
| First line | 4 (9.6) | 2 (6.4) | 2 (18.2) |
| Second Line | 34 (80.9) | 26 (84) | 8 (72.7) |
| Third line | 1 (2.4) | 1 (3.2) | 0 (0) |
| Fourth line | 3 (7.1) | 2 (6.4) | 1 (9.1) |
We finally evaluated also the impact of IgM-RF positivity on patients’ OS (Fig. S3). RFpos patients resulted in a statistically significant reduction of the OS ($p = 0.034$, Kaplan–Meier method and log-rank tests) showing a robust decrease of the median survival (90 days versus 300 days) when compared to RFneg patients. This data confirmed that the presence of IgM-RF is a prognostic factor for a poor outcome of NSCLC patients.

To conclude, based on the rate of early progression calculated using the data shown in Table 2 (i.e. 73% vs. 26% in the RF positive and negative group in 11 and 31 patients, respectively), assuming an alpha value of 0.05, the post-hoc power of our study is 80.9%.

3.3. IgM-RF affects T-cells function and reduce CD137+ T-cells in NSCLC patients

3.3.1. IgM-RF does not interfere with the anti-PD-1 binding to T-cells

Since RFs are autoantibodies with an affinity for the Fc fragment of the IgG class, we first hypothesized that IgM-RF could trap the circulating therapeutic antibodies (both belonging to the IgG subclass), avoiding the engagement between the drug and its target receptor PD-1 on T-cells and therefore predisposed RFpos patients to become resistant to anti-PD-1 immunotherapy. To test this hypothesis, PD-1 expression was induced by PHA stimulation in CD3+ cells isolated from PBMCs of healthy donors; then T-cells were exposed to Nivolumab and IgM-RF alone or in combination and finally stained with a fluorescent anti-PD-1 antibody. The presence of Nivolumab alone, but not of IgM-RF, completely abrogated the anti-PD-1 staining, due to its ability to cover the receptor. When IgM-RF and Nivolumab were used in combination, again the anti-PD-1 staining was not detected, thus indicating that IgM-RF did not interfere in the engagement of Nivolumab with its target on T-cells (Fig. 3a), coherently with other observations already published [20].

3.3.2. IgM-RF binds to naïve and central memory T-cells in RFpos NSCLC patients

We thus hypothesized that IgM-RF could exert a direct effect on T-cells. Indeed, the Fcμ receptor is expressed by T-cells in which it mediates the IgM binding with different effects on their functions [21–26]. To test whether IgM-RF could bind to T-cells, we first stained with a fluorescent anti-IgM antibody T-cells isolated from PBMC of healthy donor and cultured in vitro in the presence of both IgM-RF and a control IgM isolated from MM patients. IgM-RF bound more efficiently T-cells than the control IgM ($p = 0.004$, Student’s t-test) (Fig. 3b). This is probably due to the fact that IgM from MM patients are highly sialylated and quickly internalized [21,22], while IgM-RF are not. To confirm this hypothesis, T-cells were incubated with IgM-RF and stained with a fluorescent anti-IgM antibody at different time-points, demonstrating an increase of IgM-positive cells throughout the experiment (Fig. 3c). This prompt us to verify whether IgM-RF binding occurred also in vivo in NSCLC patients. As a confirmation, RFpos patients showed higher percentage of IgM-positive T-cells than RFneg Patients ($p<0.0001$, Student’s t-test) (Fig. 3d).

### Table 2

| Patient RF subgroup | Patient | IgM-RF value (IU/mL) | Early Progression |
|---------------------|---------|----------------------|-------------------|
| RFneg (< 16 IU/ml)  | PT 3    | 2.08                 | No                |
|                     | PT 4    | 6.07                 | No                |
|                     | PT 6    | 4.21                 | Yes               |
|                     | PT 7    | 4.05                 | No                |
|                     | PT 8    | 11.93                | No                |
|                     | PT 9    | 11.84                | No                |
|                     | PT 11   | 15.72                | No                |
|                     | PT 12   | 1.75                 | Yes               |
|                     | PT 14   | 5.28                 | No                |
|                     | PT 15   | 3.57                 | No                |
|                     | PT 16   | 3.97                 | No                |
|                     | PT 17   | 4.75                 | No                |
|                     | PT 19   | 11.63                | No                |
|                     | PT 20   | 4.54                 | No                |
|                     | PT 22   | 5.87                 | Yes               |
|                     | PT 24   | 11.57                | No                |
|                     | PT 25   | 9.23                 | Yes               |
|                     | PT 26   | 11.93                | Yes               |
|                     | PT 28   | 1.13                 | No                |
|                     | PT 29   | 13.54                | No                |
|                     | PT 30   | 3.78                 | No                |
|                     | PT 31   | 9.47                 | No                |
|                     | PT 32   | 1.46                 | No                |
|                     | PT 33   | 5.41                 | No                |
|                     | PT 35   | 1.04                 | Yes               |
|                     | PT 36   | 0.43                 | Yes               |
|                     | PT 38   | 13.87                | No                |
|                     | PT 39   | 3.20                 | No                |
|                     | PT 40   | 9.89                 | No                |
|                     | PT 41   | 1.49                 | No                |
|                     | PT 42   | 2.93                 | Yes               |
| RFlow (≥ 16 IU/ml and < 50 IU/ml) | PT 5    | 17.81                | Yes               |
|                     | PT 10   | 30.88                | Yes               |
|                     | PT 13   | 34.51                | No                |
|                     | PT 18   | 17.61                | No                |
|                     | PT 21   | 20.59                | Yes               |
|                     | PT 27   | 33.92                | Yes               |
|                     | PT 34   | 18.24                | Yes               |
|                     | PT 37   | 35.51                | No                |
| RFhigh (≥ 50 IU/ml) | PT 1    | 122.25               | Yes               |
|                     | PT 2    | 95.18                | Yes               |
|                     | PT 23   | 161.81               | Yes               |
When analyzing the IgM positivity on the different subsets of both CD4+ and CD8+ T-cells from RFpos patients, we noticed that IgM-RF preferentially bound to naïve (CCR7+CD45RA+) and central memory (CCR7+/CD45RA/C0) T-cells when compared to effector (CCR7/C0CD45RA+) and effector memory (CCR7/C0CD45RA/C0) T-cells (Fig. 3e), coherently with the higher expression of the FcR receptor on these two T-cell subsets [23,26]. IgM-RF could also bind with similar affinity the same T-cell subsets in vitro (Fig. S4).

3.3.3. IgM-RF bound to T-cells impedes T-cell migration but not proliferation

We then sought to assess if this binding of IgM-RF to T-cells could affect their functions. Therefore, we tested in vitro the proliferative and migratory ability of T-cells after exposure to IgM-RF. Since IgM-RF preferentially binds naïve and central memory T-cells, both positive for the CCR7 receptor, we used the CCL19 chemokine as chemoattractant in a migration assay. IgM-RF significantly decreased T-cells migration (p = 0.0001, Anova test) without affecting both their proliferation and CCR7 expression. IgM from MM patients used as control were able to reduce T-cell proliferation, as previously shown [22], without affecting their migration (Fig. 3f). This seems to be also coherent with the physiological role of RFs in limiting an overstated immune response [27,28].

3.3.4. CD137+T-cells are reduced in IGM-RF positive patients and affect NSCLC patients’ outcome

We then reasoned that IgM-RF could impact the activation status of T-cells also in vivo, by modulating naïve and central memory T-cell migration. We therefore performed the immunophenotype of T-cell subsets of our NSCLC patients at T0, finding that RFpos patients had the same amount of PD-1+T-cells, targeted by anti-PD-1 ICIs (data not shown), but significantly lower percentages of CD137+ T-cells (p = 0.02, Student’s t-test) (Fig. 3g). This T-cell subset has been largely identified as the real tumor-reactive T-cell population, even when present in peripheral blood [13,14,29]. In line with that, when we divided our patients based on the percentage of CD137+ T-cells at T0, we found that patients with the higher percentage of this population had a marked benefit in terms of PFS (p = 0.0064, Kaplan–Meier method and log-rank tests) with a median survival of 240 days for patients that had more than 0.65% of CD137+T-cells versus 82.5 days for patients with less than 0.65% of CD137+ T-cells (Fig. 4a). An higher percentage of CD137+T-cells in peripheral blood of patients at baseline resulted also as an important independent prognostic factor for a better OS (p = 0.0027, Kaplan–Meier method and log-rank tests) after the anti-PD-1 treatment, with a sharply better median OS for patients that had more than 0.65% of CD137+T-cells (460 days vs 130 days) (Fig. 4b).

Altogether, these data suggest that the presence of IgM-RF in patient sera can interfere with migration of both naïve and central memory T-cells, thus impacting T-cells recirculation and leading to a decrease of tumor-specific T-cells. In this scenario, the therapy with ICIs directed against PD-1 results less efficient, being anti-tumor T effector cells the target of these immunotherapy drugs and in particular the CD137 population a crucial factor in determining the patients’ response.
4. Discussion

It is already well established that the success of the immunotherapies largely depends on the fitness of patients’ immune system. However, no evidence has been provided so far about the possible presence of markers that can be the spy of a dysfunction of those immune cells that are directed against the tumor and are the target of ICI-based immunotherapies. The “quality” of T-cells, including optimal activation and trafficking to the target site, is crucial for all the immune-based drugs to be effective. Several of the immunotherapies that are available nowadays for clinical practice have indeed T-cells as target. The anti-PD-1 monoclonal antibodies Nivolumab and Pembrolizumab are doubtless two of the most exploited drugs [30]. Although the great benefits that the anti-PD-1 ICIs have brought in the treatment of advanced and metastatic NSCLC patients, several of them do not respond to the treatment. Since both Nivolumab and Pembrolizumab are directed against tumor-reactive T effector cells, an impairment of these cells can easily lead to the failure of the therapy. Various mechanisms of T-cells dysfunction in cancer have already been outlined and could serve in the future to develop novel strategies in order to improve the survival of patients undergoing T-cells-based immunotherapies [31]. Unfortunately, so far it is not possible to predict if a patient will respond or not to a certain drug.

In this retrospective study, we describe for the first time the auto-antibody IgM-FR as possible biomarker of T-cells fitness and capability to respond to ICIs in NSCLC. In fact, we showed that NSCLC patients positive for IgM-RF are more prone to develop an early progression after the anti-PD1 treatment. It is quite interesting to notice that in the past there have been few reports describing the possible association between RF and an increased risk of developing cancer [7–10], tumor recurrence and load [11,12]. Today we can probably speculate that the mechanisms underlying those observations can be

![Kaplan-Meier curves of Progression-Free Survival after the anti-PD1 treatment.](image-url)

Fig. 2. IgM-RF and Progression Free Survival. Panel a shows the Kaplan-Meier representation of Progression-free survival after the anti-PD1 treatment among the patients divided into RFpos vs RFneg (left) and RFneg vs RFhigh subgroups (right); ms = median survival; p values have been calculated using Kaplan–Meier method and log-rank tests. Panel b shows the univariate (UVA) and two different models of multivariate (MVA) analysis used to study the effect of the different clinic-pathological variables on patients’ PFS; hazard ratios (with 95% confidence intervals) and p values are shown; p values have been calculated using Kaplan–Meier method and log-rank tests for UVA and Cox proportional hazards regression analysis for MVA.
tested, including as a variable both the IgM-RF values and the outcome. Furthermore, the IgM statistical power as a prognostic factor based on RF subgroups, high IgM-RF titers correlated with a worse prognosis and a lower OS of NSCLC patients. Indeed, at the UVA it has already been demonstrated that autoantibodies in RA and in particular IgG-RF, have a lower sialylation level if compared to their normal counterpart [34,35], although direct proof of low sialylation of IgM-RF is lacking.

This is probably due to the effect of IgM-RF on naïve and central memory T-cells, in which it impairs their migratory but not their proliferative ability with no effect on PD-1 availability. Some authors highlighted how IgM can bind to T-cells both in vivo and in vitro, through the Fcμ (Toso) receptor [21–26]. The effect of this binding is however controversial. This is probably due to the diversity in post-translational modification occurring between different types of IgM. Indeed, the sialylated IgM can be internalized by T-cells, impairing their ability to proliferate, while IgM with low sialylation remain on T-cells surface and do not impact cell proliferation [22]. Interestingly, it has already been demonstrated that autoantibodies in RA and in particular IgG-RF, have a lower sialylation level if compared to their normal counterpart [34,35], although direct proof of low sialylation of IgM-RF is lacking.

IgM-RF preferentially binds naïve and central memory T cells, most probably affecting a correct homing and a subsequent expansion of a CD137+ T-cells population directed against cancer cells. In this way the treatment with Nivolumab or Pembrolizumab loses its validity as predictor biomarker in the subgroups identified by old age (>68) and ECOG PS =2. These findings appear in agreement with those previously described in the literature concerning the independent negative impact of patients’ general health conditions on ICIs effectiveness, being their target population not properly activated. The hypothesized scenario appears somehow paradoxical, with T-cells surface and do not impact cell proliferation [22]. Interestingly, it has already been demonstrated that autoantibodies in RA and in particular IgG-RF, have a lower sialylation level if compared to their normal counterpart [34,35], although direct proof of low sialylation of IgM-RF is lacking.

IgM-RF preferentially binds naïve and central memory T cells, most probably affecting a correct homing and a subsequent expansion of a CD137+ T-cells population directed against cancer cells. In this way the treatment with Nivolumab or Pembrolizumab loses its validity as predictor biomarker in the subgroups identified by old age (>68) and ECOG PS =2. These findings appear in agreement with those previously described in the literature concerning the independent negative impact of patients’ general health conditions on ICIs effectiveness, being their target population not properly activated. The hypothesized scenario appears somehow paradoxical, with T-
cells theoretically capable to be unleashed by ICI treatment from a negative regulatory constrains but unable to exert a correct homing and thus being activated against target cells in a previous step. This hypothesis could most probably apply also for other drugs that relay on T-cells as final effectors and for other tumor settings, being T-cells recirculation and CD137+ T-cells expansion critic in most of tumor models [14,29]. As a confirmation, when we stratified our patients based on the percentage of CD137+ T-cells at a baseline, it clearly resulted that those patients that undergo the ICIs treatment with a larger expansion of this population are the patients that will benefit the most from the immunotherapy, in terms of both PFS and OS. These data strongly indicate that the expansion of the CD137+T-cell population is a critical element in driving the patients towards a positive outcome in response to the anti-PD-1 treatment.

We consider these findings fundamental from two different points of view. Firstly, it confirms that T-cells need to be present and in a perfect shape, with all their functions conserved, so that the immunotherapies can be truly effective. This fact should encourage oncologists to investigate the immune system fitness of their patients before starting an immune-based treatment, moving towards what should become a personalized immunotherapy, considering the patient and her/his own immune system as the keystone to orient the therapeutic plan. On the other side, we are providing a specific biomarker, already standardized for clinical use, that can be easily tested before the patient undergoes an immunotherapy and predict whether the patient is prone to respond to the immune treatment or not. In this way, it would be possible to modulate the therapeutic strategy in order to offer the patient more chances of becoming a responder.

The main limitation of this study is the reduced size of our sample of patients, which classify our results as preliminary. Given the number of statistical tests and the minimal sample size, the calculated p-values have been corrected for multiple tests using the Bonferroni adjustment. Unfortunately, the Bonferroni adjustment of p-value is recognized to be too conservative, so real differences might be missed. Nevertheless, our study is the first to provide some comparative insights on the impact of new variables such as IgM-RF and the percentage of CD137+ T-cells on PFS and OS of NSCLC patients in treatment with the anti-PD-1 and can be considered an exploratory study. In fact, a better characterization of the mechanism and larger studies including higher numbers of patients and different types of tumors will be needed to definitely bring the dosage of IgM-RF in cancer patients in the routine clinical practice.

5. Contributors

Conceptualization, M.N., Fu.C., A.B. and A.U.; methodology, A.U., L.S., Fu.C., T.C. and H.R.; validation, A.U, I.G.Z. and L.S.; resources, P.M., G.V. and Fa.C.; data curation, A.U. and L.S.; writing - original draft preparation, A.U.; writing - review and editing, A.R., I.G.Z., M.N., Fu.C, A.B. and L.S.; visualization, A.R., M.N. and I.G.Z.; project administration, M.N.; funding acquisition, M.N.

All authors had access to the raw data and had responsibility for the decision to submit the article for publication. All authors approved the final version of the manuscript.

A.U., M.N., Fu.C. and A.B. can verify the accuracy of the raw data.

Declaration of competing interest

All authors declare no competing interests.

Acknowledgments

The research was partly supported by AIRC, MIUR and “Sapienza” University of Rome (no grant numbers are applicable). We want to acknowledge BMS for the kind gift of the drug Nivolumab.

Data sharing

Individual participant data that underlie the results reported in this article, after de-identification, study protocol, informed consent form and statistical analysis plan will be available immediately following publication, with no end date, with researchers who provide a methodologically sound proposal, to achieve aims in the approved proposal. Proposals should be directed to marianna.nuti@uniroma1.it to gain access; data requestors will need to sign a data access agreement.
Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ebiom.2020.103098.

References

[1] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017. doi:10.1016/j.cell.2017.01.017.
[2] Zaenker F, Gray ES, Ziman MR. Autoantibody production in cancer—the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev 2016. doi:10.1016/j.autrev.2016.01.017.
[3] Van Zeben D, Hazes JMW, Zwinderman AH, Cats A. Van Der Voort EAM, Breedveld FC, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis Rheum Dis 1992;51:1029–35.
[4] Steiner G, Smolen JS. Autoantibodies in rheumatoid arthritis: prevalence and clinical significance. Rheum. Arthritis 2006:193–8.
[5] Dörner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004;16:246–53. doi:10.1097/00002281-200405000-00013.
[6] Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers 2013:35:727–34, 734. doi:10.1155/2013/726598.
[7] Allander E, Björnsson OJ, Kolbeinsson A, Sigfusson N, Thorsteinsson J. Rheumatoid factor in Iceland: a population study. Int J Epidemiol 1972;1:211–23.
[8] Thorsteinsson J, Björnsson O, Kolbeinsson A, Allander E, Sigfusson N, Olafsson O. A population study of rheumatoid factor in Iceland. A 5-year follow-up of 50 women with rheumatoid factor (RF). Ann Clin Res 1975;7:183–94.
[9] Ajanova S, Humphreys JH, Verheul MK, Van Steenbergen HW, Van Nies JAB, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis 2016:75. doi:10.1136/annrheumdis-2015-208579.
[10] Ahn JK, Hwang J, Chang Y, Ryu S. Rheumatoid factor positivity increases all-cause and cancer mortality: a cohort study. Rheumatol Int 2017. doi:10.1007/s00296-017-3738-x.
[11] Gupta NP, Malaviya AN, Singh SM. Rheumatoid factor: correlation with recurrence in transitional cell carcinoma of the bladder. J Urol 1979:121.
[12] Schattner A, Shani A, Talpaz M, Bentwich Z. Rheumatoid factors in the sera of patients with gastrointestinal carcinoma. Cancer 1983:52. doi:10.1002/1097-0142(19831201)52:11<2156::AID-CNCR2820521130>3.0.CO;2-2.
[13] Zhu Y, Chen L. CD137 as a biomarker for tumor-reactive T cells: finding gold in the elusive IgM Fc receptor (FcμR) in humans. J Exp Med 2009. doi:10.1084/jem.20091107.
[14] Liu J, Wang Y, Xiong E, Hong R, Lu Q, Ohno H, et al. Role of the IgM Fc receptor in immunity and tolerance. Front Immunol 2019. doi:10.3389/fimmu.2019.00525.
[15] Murakami Y, Narayanan S, Su S, Childs R, Krezowski, Borrego F, et al. A functional IgM receptor, Is Regulated by IL-2 in T and NK Cells. J Immunol 2012. doi:10.4049/jimmunol.1200840.
[16] Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002:104:1–13.
[17] Goodwin JS, Searles RP, Tung KSK. Immunological responses of a healthy elderly population. Clin Exp Immunol 1982:48:403–10.
[18] Van Schaardenburg D, Lagay AM, Breedveld FC, Hj mans W, Vanderbroucke JP. Rheumatoid arthritis in a population of persons aged 85 years and over. Rheumatology 1993;32:104–8. doi:10.1093/rheumatology/32.2.104.
[19] Ursun J, Bos WH, van de Stadt RJ, Dijkmans BAC, van Schaardenburg D. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems. Arthritis Res Ther 2009:11. doi:10.1186/ar2794.
[20] Jones JD, Shyu I, Newkirk MM, Rigby WFC. A rheumatoid factor paradox: induction of rituximab effector function. Arthritis Res Ther 2013:15. doi:10.1186/ar4152.
[21] Colucci M, Cassetti R, Rosado MM, Casciolli S, Bruschi M, Candelaro G, et al. Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome. Kidney Int 2019. doi:10.1016/j.kint.2019.04.006.
[22] Colucci M, Stöckmann H, Butera A, Masotti A, Baldassarre A, Giorda E, et al. Sialylation of N-Linked Glycans Influences the Immunomodulatory Effects of IgM on T Cells. J Immunol 2015. doi:10.4049/jimmunol.1402025.
[23] Meryk A, Pangrazi L, Hagen M, Hatzmann F, Jenewein B, Jakic B, et al. Fcy receptors as a costimulator molecule for T cells. Cell Rep 2019. doi:10.1016/j.celrep.2019.02.024.
[24] Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med 2009. doi:10.1084/jem.20091107.
[25] Liu J, Wang Y, Xiong E, Hong R, Lu Q, Ohno H, et al. Role of the IgM Fc receptor in immunity and tolerance. Front Immunol 2019. doi:10.3389/fimmu.2019.00525.
[26] Murakami Y, Narayanan S, Su S, Childs R, Krezowski, Borrego F, et al. A functional IgM receptor, Is Regulated by IL-2 in T and NK Cells. J Immunol 2012. doi:10.4049/jimmunol.1200840.
[27] Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002:104:1–13.
[28] Westwood OMR, Nelson PN, Hay FC. Rheumatoid factors: what’s new? Rheumatology 2006:45:379–85. doi:10.1093/rheumatology/kei228.
[29] Zizzari IG, Napoletano C, Botticelli A, Capronetto S, Calabrò F, Gobieti A, et al. TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway. Cancer Immunol Res 2018. doi:10.1158/2326-6066.CIR-17-0594.
[30] Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol 2017. doi:10.1053/j.seminoncol.2017.06.007.
[31] Rieth J, Subramanian S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. Int J Mol Sci 2018. doi:10.3390/ijms19051346.
[32] D. S, L. S, D. W, J. C, M. H, R. J, et al., et al. Is Nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? results of checkmate 203. J Immunol 2015. doi:10.4049/jimmunol.1200840.
[33] Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002:104:1–13.
[34] Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol 2017. doi:10.1053/j.seminoncol.2017.06.007.
[35] Rieth J, Subramanian S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. Int J Mol Sci 2018. doi:10.3390/ijms19051346.
[36] Wu X, Liu J, Shi L, et al. Fcγ receptors as a costimulator molecule for T cells. Cell Rep 2019. doi:10.1016/j.celrep.2019.02.024.